← Amicus Therapeutics, Inc. (FOLD) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Amicus Therapeutics, Inc. (FOLD)
Pharmaceutical Preparations · market cap $4.5B · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-31 (est.)
Phase 3
Pipeline
11
programs
Upcoming events
4
next 90d+
Dossier
Ready
cached
Amicus Therapeutics (FOLD) is a Princeton, NJ-based rare disease biopharmaceutical company that, as of April 2026, became a subsidiary of BioMarin Pharmaceutical. The company focuses on lysosomal storage disorders including Pompe disease and Fabry disease, with a commercially generating pipeline (2025 revenue $634M) and multiple Phase 3 assets. Market cap stands at approximately $4.55B at a share price of ~$14.49.
The catalyst path
- 2026-12-31 (est.)Phase 3 · migalastat HCl 150 mgimp 9/10
- 2027-03-15 (est.)Phase 3 · Miglustatimp 9/10
- 2027-04-15 (est.)Phase 3 · Cipaglucosidase Alfaimp 9/10
- 2027-07-15 (est.)Phase 3 · Cipaglucosidase Alfaimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Miglustat | Phase 3 | Pompe Disease (Late-onset) |
| AT2221 | Phase 3 | Pompe Disease (Late-onset) |
| Cipaglucosidase Alfa | Phase 3 | Pompe Disease (Late-onset) |
| Afegostat tartrate | Phase 2 | Gaucher Disease, Type 1 |
| Migalastat HCl 20 mg | Phase 3 | Fabry Disease |
| migalastat hydrochloride | Phase 3 | Fabry Disease |
| duvoglustat | Phase 2 | Pompe Disease |
| ATB200 | Phase 3 | Pompe Disease |
| migalastat HCl | Phase 2 | Fabry Disease |
| migalastat HCl 150 mg | Phase 3 | Fabry Disease |
| Agalsidase Beta | Phase 2 | Fabry Disease |
Price & technical context
3-month
+1.5%
6-month
+69.5%
12-month
+104.1%
52-wk range
$5.64–$14.49
vs 50-day MA
+0.6%
vs 200-day MA
+33.7%
Realized vol
43.2%
Max drawdown
-53.3%
Daily closes through 2026-04-24. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for FOLD (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 11 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.